Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005169 | 0.89 | FPR2 (0.39) | FPR2MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL23005174 | 0.88 | FPR2 (0.38) | FPR2MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL23005141 | 0.85 | FPR2 (0.40) | FPR2MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL21494627 | 0.80 | FPR2 (0.65) | FPR2MTHFD1MTHFD2 | |
| SCHEMBL23005198 | 0.79 | EPOR (0.32) | FPR2 | |
| SCHEMBL23005121 | 0.76 | ALDH1A1 (0.35) | MAPTKMT2AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL23005242 | 0.73 | RORC (0.38) | FPR2MTHFD1MTHFD2 | |
| SCHEMBL23005249 | 0.72 | FPR2 (0.63) | FPR2KDM4EHPGDFOLH1MTHFD1 | |
| SCHEMBL23005252 | 0.72 | FPR2 (0.63) | FPR2KDM4EHPGDFOLH1MTHFD1 | |
| SCHEMBL23005116 | 0.71 | FPR2 (0.31) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | MEDICINSK FORSKNING (SE) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | FPR2 435/4885MAPT 2335/4885KMT2A 2317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.